Medicine and Dentistry
Overall Survival
87%
Transitional Cell Carcinoma
70%
Cystectomy
51%
Robot-Assisted Prostatectomy
50%
Prostate Cancer
50%
Pembrolizumab
49%
Partial Nephrectomy
41%
Clear Cell Renal Cell Carcinoma
35%
Kidney Metastasis
33%
Bladder Cancer
31%
Prognostic Factor
30%
Continence
29%
Progression Free Survival
28%
Neoplasm
27%
Cancer Specific Survival
27%
Gemcitabine
26%
Nephroureterectomy
25%
Retrospective Study
24%
Nivolumab
24%
Enfortumab Vedotin
24%
Disease
22%
Cisplatin
21%
Multivariate Analysis
20%
Urinary System
19%
Recurrence Free Survival
19%
Urinary Diversion
19%
Neutrophil
19%
Lymphocyte
18%
Postoperative Ileus
17%
Adjuvant Chemotherapy
16%
Immune-Related Adverse Events
16%
Retroperitoneal Lymph Node Dissection
16%
Neoadjuvant Chemotherapy
16%
Invasive Bladder Cancer
16%
Bladder
16%
High Risk Population
16%
Intraarterial Drug Administration
15%
Bleeding
15%
Recurrent Disease
15%
Adverse Event
14%
Geriatrics
14%
Anticarcinogen
13%
Urine Incontinence
12%
Nephrectomy
12%
Prostatectomy
12%
Propensity Score Matching
11%
Operation Duration
11%
Castration Resistant Prostate Cancer
11%
Hemodialysis
11%
Body Mass Index
10%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Bladder Cancer
77%
Castration Resistant Prostate Cancer
49%
Gemcitabine
48%
Transitional Cell Carcinoma
45%
Disease
44%
Kidney Metastasis
43%
Pembrolizumab
41%
Renal Cell Carcinoma
41%
Adverse Event
39%
Anticarcinogen
38%
Neoplasm
35%
Nivolumab
33%
Cisplatin
32%
Chemotherapy
31%
Hemodialysis
28%
Malignant Neoplasm
27%
Survival Rate
25%
Prostate Specific Antigen
25%
Recurrent Disease
24%
Prostate Cancer
24%
Progression Free Survival
23%
Enzalutamide
19%
C Reactive Protein
18%
Abiraterone Acetate
17%
microRNA 145
16%
Cabazitaxel
16%
Muscle Invasive Bladder Cancer
16%
Ipilimumab
16%
Enfortumab Vedotin
16%
Cancer Specific Survival
15%
Biochemical Recurrence
12%
Bladder Tumor
12%
Disease Exacerbation
12%
Biological Marker
12%
Androgen
11%
Recurrence Free Survival
11%
Docetaxel
11%
Abiraterone
10%
Recurrence Risk
9%
Immunotherapy
9%
Combination Therapy
9%
Androgen Receptor
9%
Heat Shock Protein 27
8%
Lymph Node Metastasis
8%
Polypyrimidine Tract Binding Protein
8%
Racemase
8%
Delayed Graft Function
8%
Synapsin I
8%
Heart Death
8%
Keyphrases
Overall Survival
30%
Pembrolizumab
24%
Metastatic Urothelial Carcinoma
16%
Metastatic Renal Cell Carcinoma (mRCC)
16%
Nephroureterectomy
16%
Upper Tract Urothelial Carcinoma
16%
Prognostic Impact
16%
Robot-assisted Radical Prostatectomy
16%
Neutrophillymphocyte Ratio
16%
CDDP
16%
Bladder-sparing
16%
Balloon-occluded Arterial Infusion
16%
Invasive Bladder Cancer
16%
Cystectomy
13%
Complete Response
12%
Partial Nephrectomy
11%
Locally Invasive
11%
Medical Colleges
10%
Osaka
10%
Clinical Response
10%
Urothelial Carcinoma
10%
Multi-institutional
10%
Bladder
10%
Oncological Outcomes
10%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
9%
Bicalutamide
9%
Microvascular Invasion
9%
Software Analysis
8%
Aortic Fistula
8%
Ureteral Stenting
8%
Flow Obstruction
8%
Tensin Homolog
8%
Abdominal Aortic
8%
Tramadol
8%
Transrectal Ultrasound
8%
Leiomyosarcoma
8%
Scrotum
8%
Pathologic
8%
Innovative System
8%
Outlet Obstruction
8%
Ultrasound-guided Core Needle Biopsy
8%
Total Cell-free DNA
8%
Oral Tramadol
8%
Promoting Factors
8%
Deep Ensemble
8%
TURis
8%
Urethral Stricture
8%
Robot-assisted Radical Nephrectomy
8%
Prognostic Value
8%
Bipolar Transurethral Resection of the Prostate
8%
